Search results for "weekly"

showing 10 items of 13 documents

Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Pr…

2004

Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor (G-CSF) support in chemonaive small-cell lung cancer patients with extensive disease (ED-SCLC). Methods: Chemonaive ED-SCLC patients received cisplatin 30 mg/sqm, epirubicin 50 mg/sqm and paclitaxel 120 mg/sqm, weekly, with G-CSF (5 μg/kg from day 3 to 5) support, for a maximum of 12 weeks. Results: Thirty-nine patients were treated, for a total of 354 cycles delivered. Eight complete (21%), and 22 partial responses (56%) were recorded, giving a 77% (95% Cl = 61-89%) objective response rate (ORR). After 14 (rang…

AdultMaleLung NeoplasmsPaclitaxelMiddle AgedPrognosisSmall-cell lung cancer Weekly chemotherapy Paclitaxel Epirubicin CisplatinSurvival AnalysisDrug Administration ScheduleTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansFemaleCarcinoma Small CellCisplatinInfusions IntravenousAgedEpirubicin
researchProduct

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a p…

2008

This is a phase II institutional exploratory trial of biweekly irinotecan and cetuximab administration regimen in metastatic colorectal cancer patients progressing to at least one previous chemotherapy line. A total of 40 patients were treated between November 2005 and November 2007 with irinotecan 180 mg m−2 and cetuximab 500 mg m−2 q2w (every 2 weeks), in every 21-day cycles, until unacceptable toxicity or progressive disease. An overall response rate of 22.5% was obtained (two complete and seven partial responses). The disease control rate was 60%. The time to progression was 3.4 months and the overall survival was 8 months. The toxicity compared very favourably to weekly cetuximab combi…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentCetuximabAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineHumansProspective StudiesNeoplasm MetastasisAdverse effectAgedChemotherapyCetuximabbusiness.industrymetastatic colorectal cancerbiweekly scheduleAntibodies MonoclonalMiddle Agedmedicine.diseaseSurgeryClinical trialIrinotecanRegimenOncologyCamptothecinFemaleColorectal NeoplasmsbusinessProgressive diseasemedicine.drugBritish Journal of Cancer
researchProduct

Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: patients’ and doctors’ views

2011

Treatment of malignant melanoma with IFN-α has been associated with significant side-effects. The aim of this retrospective monocentric non-randomized study was first to evaluate the impact on quality of life (QOL) in 30 melanoma patients treated with once weekly 2 μg/kg PEG-IFN-α2b for 18 months, and second to examine whether there is a difference in patients' and physicians' perception of QOL. Data on QOL were collected by means of the EORTC QLQ-C30 questionnaire completed by the patient before consultation at baseline and every three months during treatment. A second questionnaire was filled out independently by the physician, based on the consultation and patient file. All data were rou…

AdultMalemedicine.medical_specialtyAdolescentEvery Three Monthsmedicine.medical_treatmentOnce weeklyDermatologyInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultAmbulatory careQuality of lifePegylated interferonHumansMedicineIn patientMelanomaAgedRetrospective StudiesAged 80 and overbusiness.industryMelanomaInterferon-alphaMiddle Agedmedicine.diseaseRecombinant ProteinshumanitiesChemotherapy AdjuvantQuality of LifePhysical therapyFemalebusinessAdjuvantmedicine.drugEuropean Journal of Dermatology
researchProduct

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of …

2006

Abstract Background Elderly patients have been often excluded from or underrepresented in the study populations of combination chemotherapy trials. The primary end point of this study was to determine the response rate and the toxicity of the weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) regimen in elderly patients with advanced gastric cancer. The secondary objective was to measure the time to disease progression and the survival time. Methods Chemotherapy-naive patients with advanced gastric cancer aged 70 or older were considered eligible for study entry. Patients received weekly oxaliplatin 40 mg/m2, fluorouracil 500 mg/m2 and folinic acid 250 mg/m2. All drugs were given i…

MaleOncologymedicine.medical_specialtyCancer ResearchOrganoplatinum Compoundsmedicine.medical_treatmentlcsh:RC254-282Drug Administration ScheduleLEUCOVORINFolinic acidEPI-DOXORUBICINTRACT CANCERCISPLATINADVANCED ESOPHAGOGASTRIC CANCERStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointGeneticsHumansAged6S-LEUCOVORINAged 80 and overCisplatinChemotherapybusiness.industryCombination chemotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensINFUSIONAL FLUOROURACILRANDOMIZED-TRIALOxaliplatinOxaliplatinSurvival RateRegimenOncologyFluorouracilINTENSIVE WEEKLY CHEMOTHERAPYETOPOSIDEFemaleFluorouracilbusinessResearch Articlemedicine.drug
researchProduct

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy

2010

Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisLung NeoplasmsWEEKLY DOCETAXELIRINOTECANCOMBINATION CHEMOTHERAPYAntineoplastic AgentsERLOTINIBPrognostic factorsNSCLCTHERAPYPooled analysisPLUS GEMCITABINEInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Lung cancerEVERY 3 WEEKSAgedNeoplasm StagingRandomized Controlled Trials as TopicAged 80 and overPerformance statusProportional hazards modelbusiness.industryAge FactorsCombination chemotherapyPHASE-III TRIALMiddle Agedmedicine.diseasePrognosisTreatment OutcomeOncologyMeta-analysisPrognostic scoreCOMPARING DOCETAXELSecond-line treatmentAdenocarcinomaFemalebusinessEpidemiologic MethodsNon-small-cell lung cancerEuropean Journal of Cancer
researchProduct

Weekly docetaxel in the treatment of metastatic breast cancer

2008

Breast cancer is the most frequent tumor among women worldwide and is the second cause of cancer-related mortality in the US. Metastatic breast cancer (MBC) accounts for less than 10% of newly diagnosed breast cancer patients and about 30% of early breast cancer patients will develop recurrent, advanced, or metastatic disease. It remains an incurable illness and the primary goal of its management is palliative. Several agents are active for the fi rst-line treatment of MBC. The taxanes, paclitaxel and docetaxel, represent the standard of care for the treatment of these patients. Among the various schedules, docetaxel can be administered weekly, achieving similar effi cacy results with lower…

Oncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentReviewDiseasechemotherapyDOCETAXEL WEEKLYMETASTATIC BREAST CANCERCHEMOTHERAPYlaw.inventionchemistry.chemical_compoundBreast cancerRandomized controlled triallawInternal medicinemedicinedocetaxelPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsChemotherapyChemical Health and Safetybusiness.industryGeneral Medicineweeklymedicine.diseaseMetastatic breast cancerSurgeryDocetaxelPaclitaxelchemistryToxicitymetastatic breast cancerbusinessSafety Researchmedicine.drugTherapeutics and Clinical Risk Management
researchProduct

Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER)

2013

WOS: 000319897700018

RegistrieSevere bleedingAdultMalePediatricsmedicine.medical_specialtyTime FactorsTime FactorAdolescentFactor VII DeficiencyPROPHYLAXIS FACTOR VII DEFICIENCYFactor VIIachemistry.chemical_compoundPlasmaYoung AdultMedicineHumansRegistriesYoung adultFactor VII deficiencyChildFactor VIIbusiness.industryInfantHematologyRecombinant ProteinFactor VIIMiddle Agedmedicine.diseaseThrombosisRecombinant ProteinsClinical trialTreatment OutcomechemistryTreatment evaluationWeekly doseChild PreschoolFemaleOriginal Articles and Brief ReportsbusinessHuman
researchProduct

Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly…

2016

Background: To evaluate the feasibility and clinical preliminary results of weekly cisplatin and volumetric-modulated arc therapy to the pelvis with simultaneous integrated boost to macroscopic disease in a cohort of elderly patients. Materials and Methods: Inclusion criteria of this prospective study were age ≥70 years, Karnofsky performance status 70 to 100, locally advanced histologically proven squamous cervical carcinoma, and patients unable to undergo brachytherapy. Radiation doses prescribed were 66 Gy to the macroscopic disease and 54 Gy to the pelvic nodes in 30 fractions. Weekly cisplatin dose was 40 mg/mq. Results: A total of 30 patients were recruited. Median follow-up was 32 mo…

Simultaneous integrated boostMalemedicine.medical_specialtyCancer ResearchBrachytherapyUterine Cervical NeoplasmsVMATelderly patients030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineWeekly cisplatinmedicineArc therapyHumansAgedCervical cancerRadical treatmentAged 80 and overbusiness.industryRadiotherapy DosageArticlesmedicine.diseaseVolumetric modulated arc therapyCombined Modality TherapySurgeryOncology030220 oncology & carcinogenesisCarcinoma Squamous CellVMAT; advanced cervical cancer; elderly patients; gynecological malignanciesFemaleadvanced cervical cancer; elderly patients; gynecological malignancies; VMAT; Oncology; Cancer ResearchRadiologyDose Fractionation RadiationLymph NodesRadiotherapy Intensity-ModulatedCisplatinbusinessgynecological malignanciesadvanced cervical cancer
researchProduct

Mesurer l'effet du travail salarié sur la réussite : une analyse statistique sur les étudiants d'une université française

2018

L’emploi étudiant est généralement considéré comme un frein à la réussite scolaire et universitaire. Nos travaux portant sur une enquête réalisée dans une université française en 2012 visent à mesurer les effets des caractéristiques de l’emploi et, notamment, de son intensité. À partir d’une modélisation statistique prenant en compte la probabilité d’accès au travail salarié, nous montrons un effet négatif de l’emploi salarié pour les étudiants qui travaillent plus de 8 heures par semaine. Le type d’emploi exercé a également un effet sur les chances de réussite : les jeunes ayant un emploi dans le secteur public et ceux qui ont la possibilité d’aménager leur emploi du temps paraissent moins…

Social Sciences and HumanitiesRéussite universitairetemps de travail par semainetempo de trabalho por semana[SHS.EDU]Humanities and Social Sciences/Educationweekly working timeEnseignement supérieur0502 economics and businessemprego durante os estudos050207 economicssucesso universitárioEffet05 social sciences050301 education[ SHS.EDU ] Humanities and Social Sciences/EducationGeneral MedicineTravail salariéacademic achievementUniversitéÉtudiant salariéTemps de travailSciences Humaines et Socialesemploi durant les étudesFrancestudent employment0503 education
researchProduct

Amerikkalaiset ja Saksan pakolaiskysymys Weekly Information Bulletin -tiedotuslehdessä vuosina 1945-1953

2011

Toinen maailmansota johti vaikeaan pakolaisongelmaan, jonka keskuksena oli antautunut Saksa. Alueella oleskelleet pakolaiset tulivat hyvin erilaisista lähtökohdista ja pakolaisten määrä kohosi useisiin miljooniin. Ongelmien ratkaisu oli Saksaa miehittäneiden liittoutuneiden vastuulla. Tämän tutkielman aiheena on amerikkalaisten vuosina 1945–1953 Saksassa julkaiseman tiedotuslehden Weekly Information Bulletinin (WIB) kirjoittelu Saksan toisen maailmansodan jälkeisestä pakolaisuudesta. Tarkastelen tutkielmassani historiallis-kvalitatiivisen lähestymistavan avulla pakolaiskirjoittelun kokonaiskuvan lisäksi sen laatua ja sävyä, sekä arvioin miksi lehti kirjoitti juuri tällä tavoin. WIB:in tärke…

Weekly Information Bulletintiedotuslehdetmiehitys1940-luku1950-lukuYhdysvallatpakolaisuusSaksa
researchProduct